PDCD1 and gastroesophageal junction adenocarcinoma: Many data suggest that anti-PD1/anti–PD-L1 efficacy depends on PD-L1 CPS in advanced gastric/GEJ adenocarcinoma.8,9 In PRODIGE 59-FFCD 1707-DURIGAST, PFS did not seem to vary according to PD-L1 CPS.